June 25, 2020
An enzyme has been discovered to play a critical role in blocking the metabolic processes that contribute to the rapid growth and spread of liver cancer
June 3, 2020
I am pleased to announce that Theresa Scognamiglio, MD will serve as the new Chief of Surgical Pathology effective July 1, 2020.
May 23, 2020
In March, as the COVID-19 pandemic gained a visible foothold in New York City and infected hundreds of thousands of residents, Weill Cornell Medicine and NewYork-Presbyterian faced a task unlike any they had encountered before.Laboratory technologists and accessioning staff at Weill Cornell Medicine. From left, Anqi Chen, Kathy Fauntleroy and Amy Robertson. All photos provided.How would they quickly establish a reliable diagnostic testing program to identify patients and healthcare workers who had been exposed to SARS-CoV-2, the virus that causes COVID-19, amid a rapidly escalating public...
September 10, 2019
The Pathologist has named Genevieve Crane...
May 23, 2019
March 6, 2019
Congratulations to Dr. Nicholas Brady, a post-doctoral fellow working in David Rickman’s lab, who won 1st prize for a poster and talk he presented at the 12th Annual Multi-Institutional Prostate Cancer SPORE Retreat.Nicholas is also a recipient of the NIH/NCI Molecular and Translational Oncology Research (MTOR) Training Program (7/2018 – 6/2020).
February 17, 2019
We are delighted to announce that the New York City Chapter of The Leukemia & Lymphoma Society (LLS) will be honoring Dr. Selina Chen-Kiang at the 2nd Annual Crimson Ball on Wednesday, April 24, 2019 at The Mandarin Oriental in New York City
February 17, 2019
It is with great pleasure that I announce the appointment of David P. Hajjar, Ph.D. as Executive Vice Chair of Pathology and Laboratory Medicine, effective immediately.
December 9, 2018
Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time. The findings may enable investigators to develop superior therapies that are effective, well tolerated and tailored to individual patients with mantle cell lymphoma.